Plasma C-peptide level is inversely associated with family history of type 2 diabetes in korean type 2 diabetic patients

Endocrine Journal

Volumn 57, Issue 10, 2010, Pages 931-938

  Chung, Jin Ook ^a   Cho, Dong Hyeok ^a   Chung, Dong Jin ^a   Chung, Min Young ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Family; History; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FAMILY HISTORY; FATTY ACID BLOOD LEVEL; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PROTEIN BLOOD LEVEL; SOUTH KOREA; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGE OF ONSET; AGED; BODY MASS INDEX; C-PEPTIDE; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA;

EID: 78649337923     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-175     Document Type: Article

References (36)

1. Marchetti P, Dotta F, Lauro D, Purrello F (2008) An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept 146: 4-11.
2. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR (1998) Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15: 290-296.
3. Klein BE, Klein R, Moss SE, Cruickshanks KJ (1996) Parental history of diabetes in a population-based study. Diabetes Care 19: 827-830.
4. Hogan P, Dall T, Nikolov P (2003) Economic costs of diabetes in the US in 2002. Diabetes Care 26: 917-932
5. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M (1998) Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. J Clin Invest 101: 86-96.
6. Grill V, Persson G, Carlsson S, Norman A, Alvarsson M, Ostensson CG, Svanström L, Efendic S (1999) Family history of diabetes in middle-aged Swedish men is a gender unrelated factor which associates with insulinopenia in newly diagnosed diabetic subjects. Diabetologia 42: 15-23.
7. Leonetti DL, Fujimoto WY, Wahl PW (1989) Early-life background and the development of non-insulin-dependent diabetes mellitus. Am J Phys Anthropol 79: 345-355.
8. Boer JM, Feskens EJ, Kromhout D (1996) Characteristics of non-insulin-dependent diabetes mellitus in elderly men: effect modification by family history. Int J Epidemiol 25: 394-402.
9. Dabelea D, Bell RA, D'Agostino RB, Jr., Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S, Mayer-Davis EJ, Pettitt DJ, Waitzfelder B (2007) Incidence of diabetes in youth in the United States. JAMA 297: 2716-2724.
10. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B (1986) Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 77: 98-105.
11. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G (2000) Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 37: 125-129.
12. Wahren J, Johansson BL, Wallberg-Henriksson H (1994) Does C-peptide have a physiological role? Diabetologia 37: S99-107.
13. Wahren J, Johansson BL, Wallberg-Henriksson H, Linde B, Fernqvist-Forbes E, Zierath JR (1996) C-peptide revisited--new physiological effects and therapeutic implications. J Intern Med 240: 115-124.
14. Holman RR (1998) Assessing the potential for alphaglucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 40: S21-25.
15. U.K. prospective diabetes study 16 (1995) Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44: 1249-1258.
16. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.
17. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M (2005) Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. BMC Public Health 5: 36.
18. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K (2010) Factors associated with poor glycemic control among patients with type 2 diabetes. J Diabetes Complications 24: 84-89.
19. Karter AJ, Moffet HH, Liu J, Parker MM, Ahmed AT, Ferrara A, Selby JV (2005) Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry. Am J Manag Care 11: 262-270.
20. Taskinen MR, Smith U (1998) Lipid disorders in NIDDM: implications for treatment. J Intern Med 244: 361-370.
21. Gong L, Kao WH, Brancati FL, Batts-Turner M, Gary TL (2008) Association between parental history of type 2 diabetes and glycemic control in urban African Americans. Diabetes Care 31: 1773-1776.
22. Lupi R, Del Guerra S, Tellini C, Giannarelli R, Coppelli A, Lorenzetti M, Carmellini M, Mosca F, Navalesi R, Marchetti P (1999) The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 364: 205-209.
23. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S (2004) Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 286: E560-567.
24. Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48: 241-253.
25. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, Scherer PE, Boyko EJ, Fujimoto WY, Kahn SE (2007) Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 30: 677-682.
26. Frayling TM, Evans JC, Bulman MP, Pearson E, Allen L, Owen K, Bingham C, Hannemann M, Shepherd M, Ellard S, Hattersley AT (2001) beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 50: S94-100.
27. Stride A, Hattersley AT (2002) Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med 34: 207-216.
28. Min HK (1992) Clinical characteristics of diabetes in Korea. Korean Diabetes J 16: 163-174 (in Korean).
29. Hariri S, Yoon PW, Qureshi N, Valdez R, Scheuner MT, Khoury MJ (2006) Family history of type 2 diabetes: a population-based screening tool for prevention? Genet Med 8: 102-108.
30. Stolerman ES, Florez JC (2009) Genomics of type 2 diabetes mellitus: implications for the clinician. Nat Rev Endocrinol 5: 429-436.
31. Matsuda A, Kuzuya T (1996) The prevalence of low insulin responders to oral glucose load among groups with various patterns of family history of diabetes. Diabet Med 13: S59-62.
32. Li H, Isomaa B, Taskinen MR, Groop L, Tuomi T (2000) Consequences of a family history of type 1 and type 2 diabetes on the phenotype of patients with type 2 diabetes. Diabetes Care 23: 589-594.
33. Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K, Hamamoto Y, Hosokawa M, Seino Y, Inagaki N (2008) Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 82: 353-358.
34. Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, Segre O, Grassi G, Cavallo-Perin P, Bruno G (2009) Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 32: 301-305.
35. Ekberg K, Brismar T, Johansson BL, Lindstrom P, Juntti-Berggren L, Norrby A, Berne C, Arnqvist HJ, Bolinder J, Wahren J (2007) C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 30: 71-76.
36. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J (2000) Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 17: 181-189.